Specificity and Mechanism of Action of Some Commonly Used Protein Kinase Inhibitors

Overview

Journal Biochem J

Specialty Biochemistry

Date 2000 Sep 22

PMID 10998351

Citations 1446

Authors

S P DAVIES

H Reddy

M Caivano

P Cohen

Affiliations

Soon will be listed here.

Abstract

The specificities of 28 commercially available compounds reported to be relatively selective inhibitors of particular serine/threonine-specific protein kinases have been examined against a large panel of protein kinases. The compounds KT 5720, Rottlerin and quercetin were found to inhibit many protein kinases, sometimes much more potently than their presumed targets, and conclusions drawn from their use in cell-based experiments are likely to be erroneous. Ro 318220 and related bisindoylmaleimides, as well as H89, HA1077 and Y 27632, were more selective inhibitors, but still inhibited two or more protein kinases with similar potency. LY 294002 was found to inhibit casein kinase-2 with similar potency to phosphoinositide (phosphatidylinositol) 3-kinase. The compounds with the most impressive selectivity profiles were KN62, PD 98059, U0126, PD 184352, rapamycin, wortmannin, SB 203580 and SB 202190. U0126 and PD 184352, like PD 98059, were found to block the mitogen-activated protein kinase (MAPK) cascade in cell-based assays by preventing the activation of MAPK kinase (MKK1), and not by inhibiting MKK1 activity directly. Apart from rapamycin and PD 184352, even the most selective inhibitors affected at least one additional protein kinase. Our results demonstrate that the specificities of protein kinase inhibitors cannot be assessed simply by studying their effect on kinases that are closely related in primary structure. We propose guidelines for the use of protein kinase inhibitors in cell-based assays.

Citing Articles

LRRC8A-containing anion channels promote glioblastoma proliferation via a WNK1/mTORC2-dependent mechanism.

Fidaleo A, Bach M, Orbeta S, Abdullaev I, Martino N, Adam A bioRxiv. 2025; .

PMID: 39975357 PMC: 11838495. DOI: 10.1101/2025.02.02.636139.

The impact of signaling pathways on the desmosome ultrastructure in pemphigus.

Schmitt T, Huber J, Pircher J, Schmidt E, Waschke J Front Immunol. 2025; 15:1497241.

PMID: 39882246 PMC: 11774707. DOI: 10.3389/fimmu.2024.1497241.

Discovery of PPAR Alpha Lipid Pathway Modulators That Do Not Bind Directly to the Receptor as Potential Anti-Cancer Compounds.

Al Subait A, Alghamdi R, Ali R, Alsharidah A, Huwaizi S, Alkhodier R Int J Mol Sci. 2025; 26(2).

PMID: 39859448 PMC: 11766124. DOI: 10.3390/ijms26020736.

Differential substrate specificity of ERK, JNK, and p38 MAP kinases toward connexin 43.

Latchford L, Perez L, Conage-Pough J, Turk R, Cusimano M, Vargas V J Biol Chem. 2025; 301(3):108178.

PMID: 39798878 PMC: 11870265. DOI: 10.1016/j.jbc.2025.108178.

Inhibition of Cardiac p38 Highlights the Role of the Phosphoproteome in Heart Failure Progression.

Sedighi S, Liu T, OMeally R, Cole R, ORourke B, Foster D bioRxiv. 2024; .

PMID: 39605458 PMC: 11601511. DOI: 10.1101/2024.11.20.624554.

References

Thomson S, Clayton A, Hazzalin C, Rose S, Barratt M, Mahadevan L . The nucleosomal response associated with immediate-early gene induction is mediated via alternative MAP kinase cascades: MSK1 as a potential histone H3/HMG-14 kinase. EMBO J. 1999; 18(17):4779-93. PMC: 1171550. DOI: 10.1093/emboj/18.17.4779. View

Yu L, Orlandi L, Wang P, Orr M, Senderowicz A, Sausville E . UCN-01 abrogates G2 arrest through a Cdc2-dependent pathway that is associated with inactivation of the Wee1Hu kinase and activation of the Cdc25C phosphatase. J Biol Chem. 1998; 273(50):33455-64. DOI: 10.1074/jbc.273.50.33455. View

Picton C, Woodgett J, Hemmings B, Cohen P . Multisite phosphorylation of glycogen synthase from rabbit skeletal muscle. Phosphorylation of site 5 by glycogen synthase kinase-5 (casein kinase-II) is a prerequisite for phosphorylation of sites 3 by glycogen synthase kinase-3. FEBS Lett. 1982; 150(1):191-6. DOI: 10.1016/0014-5793(82)81332-x. View

Cohen P . The search for physiological substrates of MAP and SAP kinases in mammalian cells. Trends Cell Biol. 2007; 7(9):353-61. DOI: 10.1016/S0962-8924(97)01105-7. View

Leopoldt D, Hanck T, Exner T, Maier U, Wetzker R, Nurnberg B . Gbetagamma stimulates phosphoinositide 3-kinase-gamma by direct interaction with two domains of the catalytic p110 subunit. J Biol Chem. 1998; 273(12):7024-9. DOI: 10.1074/jbc.273.12.7024. View

Tachibana E, Harada T, Shibuya M, Saito K, Takayasu M, Suzuki Y . Intra-arterial infusion of fasudil hydrochloride for treating vasospasm following subarachnoid haemorrhage. Acta Neurochir (Wien). 1999; 141(1):13-9. DOI: 10.1007/s007010050260. View

Nakanishi S, Kakita S, Takahashi I, Kawahara K, Tsukuda E, Sano T . Wortmannin, a microbial product inhibitor of myosin light chain kinase. J Biol Chem. 1992; 267(4):2157-63. View

Hers I, Tavare J, Denton R . The protein kinase C inhibitors bisindolylmaleimide I (GF 109203x) and IX (Ro 31-8220) are potent inhibitors of glycogen synthase kinase-3 activity. FEBS Lett. 1999; 460(3):433-6. DOI: 10.1016/s0014-5793(99)01389-7. View

Shaw M, Cohen P, Alessi D . The activation of protein kinase B by H2O2 or heat shock is mediated by phosphoinositide 3-kinase and not by mitogen-activated protein kinase-activated protein kinase-2. Biochem J. 1998; 336 ( Pt 1):241-6. PMC: 1219864. DOI: 10.1042/bj3360241. View

10.

Goedert M, Hedge P, Cohen P . Effect of SB 203580 on the activity of c-Raf in vitro and in vivo. Oncogene. 1999; 18(12):2047-54. DOI: 10.1038/sj.onc.1202603. View

11.

Sahai E, Ishizaki T, Narumiya S, Treisman R . Transformation mediated by RhoA requires activity of ROCK kinases. Curr Biol. 1999; 9(3):136-45. DOI: 10.1016/s0960-9822(99)80067-0. View

12.

Eyers P, van den Ijssel P, Quinlan R, Goedert M, Cohen P . Use of a drug-resistant mutant of stress-activated protein kinase 2a/p38 to validate the in vivo specificity of SB 203580. FEBS Lett. 1999; 451(2):191-6. DOI: 10.1016/s0014-5793(99)00552-9. View

13.

Kamakura S, Moriguchi T, Nishida E . Activation of the protein kinase ERK5/BMK1 by receptor tyrosine kinases. Identification and characterization of a signaling pathway to the nucleus. J Biol Chem. 1999; 274(37):26563-71. DOI: 10.1074/jbc.274.37.26563. View

14.

Itoh K, Yoshioka K, Akedo H, Uehata M, Ishizaki T, Narumiya S . An essential part for Rho-associated kinase in the transcellular invasion of tumor cells. Nat Med. 1999; 5(2):221-5. DOI: 10.1038/5587. View

15.

Deak M, Clifton A, Lucocq L, Alessi D . Mitogen- and stress-activated protein kinase-1 (MSK1) is directly activated by MAPK and SAPK2/p38, and may mediate activation of CREB. EMBO J. 1998; 17(15):4426-41. PMC: 1170775. DOI: 10.1093/emboj/17.15.4426. View

16.

Cohen P . The development and therapeutic potential of protein kinase inhibitors. Curr Opin Chem Biol. 1999; 3(4):459-65. DOI: 10.1016/S1367-5931(99)80067-2. View

17.

Eyers P, Cohen P, Goedert M, Boyle F, Hewitt N, Plant H . Paradoxical activation of Raf by a novel Raf inhibitor. Chem Biol. 1999; 6(8):559-68. DOI: 10.1016/s1074-5521(99)80088-x. View

18.

Fong T, Shawver L, Sun L, Tang C, App H, Powell T . SU5416 is a potent and selective inhibitor of the vascular endothelial growth factor receptor (Flk-1/KDR) that inhibits tyrosine kinase catalysis, tumor vascularization, and growth of multiple tumor types. Cancer Res. 1999; 59(1):99-106. View

19.

Davis P, Hill C, Keech E, Lawton G, Nixon J, Sedgwick A . Potent selective inhibitors of protein kinase C. FEBS Lett. 1989; 259(1):61-3. DOI: 10.1016/0014-5793(89)81494-2. View

20.

Kimura K, Ito M, Amano M, Chihara K, Fukata Y, Nakafuku M . Regulation of myosin phosphatase by Rho and Rho-associated kinase (Rho-kinase). Science. 1996; 273(5272):245-8. DOI: 10.1126/science.273.5272.245. View